Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07266584Not ApplicableRecruiting

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Role: lead

NCT03333954Not ApplicableCompleted

Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration

Role: lead

NCT03392324Not ApplicableActive Not Recruiting

PRIMA US-Feasibility Study in Atrophic Dry AMD

Role: lead

NCT04676854Not ApplicableActive Not Recruiting

Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

Role: lead

NCT02670980Not ApplicableCompleted

Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy

Role: lead

NCT01864486Not ApplicableCompleted

Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy

Role: lead

All 6 trials loaded